2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 278-282
Treatment Considerations, Supportive Care, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

727 Geriatric assessment-guided management reduces severe treatment toxicity in older adults with lymphoma

Pallawi Torka, MD, Mostafa Mohamed, MBBCh, PhD2, Hemavathi Baskarane, MD DM3, Yingzhu Chen, MS4, Rachael Tylock5, Nina Rosa Neuendorff6, Carla Jorgensen, MD7, Amy Squire8, Amarinthia Curtis9, Supriya Mohile, MD10, Kah Poh (Melissa) Loh, MD, MS11
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 University of Rochester Medical Center, Rochester, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, United States
4 University of Rochester, Rochester, United States
5 University of Rochester, Rochester, United States
6 University Duisburg-Essen, Essen, Germany
7 Prisma Health Cancer Institute, Greenville, United States
8 metro minnesota community oncology research consortium, Minnesota, United States
9 Gibbs Cancer Center & Research Institute, Spartanburg, United States
10 University of Rochester, Rochester, United States
11 University of Rochester, Rochester, United States

Background:

Older adults with lymphoma are at high risk for treatment-related toxicity, and geriatric impairments are associated with increased toxicity and inferior survival. However, lymphoma-specific evidence supporting the benefit of geriatric assessment and management (GAM) remains limited. The seminal National Cancer Institute-sponsored GAP70+ cluster-randomized trial demonstrated that a geriatric assessment-guided management intervention reduced treatment toxicity among adults aged ≥70 years with advanced cancer receiving systemic therapy (Mohile et al, Lancet 2021). We performed a subgroup analysis of patients with lymphoma enrolled in GAP70+ to evaluate the impact of GAM on treatment tolerability and clinical outcomes.

Methods:

GAP70+ enrolled patients aged ≥70 years with advanced cancer and ≥1 geriatric assessment domain impairment initiating new systemic therapy across community oncology practices randomized to usual care (UC) or GAM. Geriatric assessment evaluated eight domains: physical performance (Timed Up and Go [TUG], Short Physical Performance Battery [SPPB], falls history, OARS Physical Health), functional status (Activities of Daily Living and Instrumental Activities of Daily Living), comorbidity (OARS Comorbidity), cognition (Blessed Orientation-Memory-Concentration test and Mini-Cog), nutrition (BMI, weight loss, and Mini Nutritional Assessment), social support, polypharmacy, and psychological status (Geriatric Depression Scale [GDS] and Generalized Anxiety Disorder-7). In the GAM arm, geriatric assessment results and evidence-based recommendations were provided before treatment initiation. This ad hoc subgroup analysis included patients with lymphoma. Outcomes were grade 3–5 toxicity within 3 months, hospitalization, early treatment discontinuation, and overall survival at 6 and 12 months. Risk ratios (RRs) were estimated using generalized estimating equations accounting for practice-site clustering.

Results:

Forty-six patients were included (UC, n=23; GAM, n=23). The mean age was 77 years; 26.1% were aged ≥80 years, 63% males, 93.1% Caucasian. Most patients had stage IV disease (82.6%) and received first-line therapy (80.4%). The most common regimens were bendamustine-rituximab (32.6%) and R-CHOP (30.4%). Impaired GA domains included altered physical performance (91.3%), polypharmacy (76.1%), presence of comorbidities (73.9%), nutrition (45.7%), cognition (41.3%), functional status (39.1%), psychological (32.6%) and social support (26.1%). Mean TUG time was 12.3 seconds.  Baseline clinical characteristics and geriatric impairments were balanced between study arms.

Compared with UC, GAM was associated with lower rates of any grade 3–5 toxicity (60.9% vs 87.0%; adjusted RR 0.70, 95% CI 0.49–1.01; p=0.054) and significantly lower grade 3–5 non-hematologic toxicity (30.4% vs 56.5%; adjusted RR 0.54, 95% CI 0.30–0.95; p=0.033). Grade 3–5 hematologic toxicity was numerically lower with GAM (39.1% vs 60.9%; p=0.236). Planned cycle 1 dose modification occurred more frequently in the GAM arm (30.4% vs 21.7%; p=0.400). Hospitalization occurred less frequently with GAM (26.1% vs 43.5%; p=0.178) while early treatment discontinuation was numerically higher (21.7% vs 13.0%; p=0.213). Six-month OS was identical in both groups (82.6%; p=1.00), and 12-month OS was comparable (73.9% vs 65.2%; p=0.52).

Exploratory analyses showed that impaired TUG, lower SPPB scores, and functional impairment were associated with an increased risk of grade 3–5 non-hematologic toxicity (p=0.007, p=0.033, and p=0.015, respectively), hospitalization (p=0.004 and p<0.001 for TUG and SPPB, respectively), and early treatment discontinuation (p=0.047 for functional impairment). Higher GDS scores were associated with grade 3–5 non-hematologic toxicity (p=0.003) and hospitalization (p<0.001), while increasing number of impaired GA domains were associated with grade 3–5 non-hematologic toxicity(p=0.044), hospitalization (p=0.003), and early treatment discontinuation (p=0.003).

Conclusions:

Among older adults with lymphoma, GAM was associated with reduced severe treatment-related toxicity, particularly non-hematologic toxicity, without compromising short-term survival. These findings support integration of geriatric assessment and management into routine care for older adults with lymphoma to optimize treatment decisions and improve treatment safety in older adults.

Pallawi Torka, MD: Abbvie - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Seagen - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Lilly Oncology - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)